Due to the pivotal role played by human serum albumin (HSA) in the transport and cytotoxicity of titanocene complexes, a docking study has been performed on a selected set of titanocene complexes to help clarify the potential mode of action of these titanocenes upon binding HSA. Analysis of the docking results has revealed potential binding modes for these titanocenes at the known drug binding 5 sites in HSA. Additionally, a new alternative binding site for these titanocenes has been postulated.
Introduction
Metal-based antitumour agents have gained significant interest since the discovery of the antitumour activities of cis-platin (Fig. 1a) . 1 However, due to toxic side effects of this chemotherapeutic agent 2, 3 such as myelotoxicity and nephrotoxicity, in addition to the high risk of developing tumour resistances, research has progressed to other metal-based chemotherapeutic agents such as metallocene dihalides; 5 Cp 2 MX 2 . 4 Metallocene dihalides, containing a variety of transition metals (M= Ti, V, Nb, Mo), showed remarkable antitumour activity when tested in-vivo using simple animal models. 4 Among all the metallocenes tested, titanocene dichloride Cp 2 TiCl 2 ( Fig. 1b) was initially found to exhibit the most impressive chemotherapeutic activity against colon, lung and breast cancers. 3 Titanocene dichloride entered clinical trials in 1993, but results from phase II clinical trials in patients with advanced renal 10 cell carcinoma and breast metastatic carcinoma were not sufficiently promising 5, 6 and further clinical trials were abandoned. In general, albumin is important to cancer cells as a nutrient and energy supply in order to facilitate their rapid growth. An anti-cancer drug bound to albumin is of significant advantage as this facilitates the uptake across the endothelial cell wall of blood vessels of tumours in an albumin receptor-mediated transport pathway. In the last two decades, there has been a growing interest towards the development of new substituted titanocene dichloride derivatives (Fig. 2 ). McGowan and co-workers synthesized a number of ionic titanocenes which have improved water solubility and were found to be highly effective against ovarian cancers. 8- 10 Another series of water soluble titanocene dichloride complexes was synthesized 20 by Baird et al. and found to be effective against lung and ovarian cancers. 11 On the other hand, the current efforts by Tacke et al. have focused on the development of substituted titanocene complexes starting from substituted fulvenes. This has resulted in the synthesis of substituted titanocenes that exhibit remarkable antitumour activity against kidney carcinoma LLC-PK cell line, with IC 50 values reaching 5.4 µM range. Synthetic efforts are ongoing and aimed at developing new titanocene 25 complexes exhibiting potent cytotoxic activity along with reduced side effects and non-cross resistance.
While the exact mechanism of action of titanocene dichloride complexes is still poorly understood, several investigations have shown that both transferrin and albumin could serve as possible routes for 30 the delivery of titanocenes to cancer cells [36] [37] [38] [39] ,whereas DNA is believed to be the main cellular target for these titanocene complexes. [40] [41] [42] Tacke and co-workers have confirmed the crucial role played by binding to serum albumins in the cytotoxicity of titanocene complexes, since cancer cells are known to be leaky for albumin due to enhanced vascular permeability and retention effects. 7 Research has shown for example that Titanocene Y has only a cytotoxic effect in the presence of serum albumin when tested on the oestrogen-depending breast cancer cell line MCF-7. To date, no systematic molecular docking studies have been reported for the potential drug class titanocenes. This paper reports, for the first time, a systematic receptor-based docking approach for a database of 16 titanocene derivatives exhibiting a range of structural and biological activity in order to shed light on understanding the mode of action of these titanium-based anticancer drugs against HSA.
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Materials and Methods
The described study compromised 16 titanocene derivatives taken from the literature 12 (see Table 1 ), which constituted the dataset. The compounds were selected based on the following criteria:
1. All selected compounds are tested for their cytotoxic activity on the same cancer cell line in 10 order to enable a direct comparison of their efficacy.
2. The selected compounds are diverse in both structure and antitumour activity, expressed as IC 50 , allowing structural features to be correlated to cytotoxic activity. functionalized titanocenes 3a-c, diheteroaryl-substituted titanocenes 4a-c and diaryl-substituted titanocenes 5a-c. Moreover, these titanocenes showed a wide range of cytotoxic activity and all were tested against the same (LLC-PK) cell line using an MTT-based assay, as described in the literature 12 .
The three-dimensional structure of each titanocene derivative forming the dataset was built using the 25 Sketcher module in the molecular modeling software SYBYL. 49 The basic unit Cp 2 TiCl 2 present in all titanocenes was modelled using the force field parameters reported by Doman et al. 50 Finally, the protein structures were prepared for the docking runs using the Biopolymer Structure hydrogen bond (H-bond), van der Waals (vdW) and hydrophobic interactions generated by the docking process, the resulting PDB files from the docking runs were input to the program CONTACT, available in the CCP4 programme suite. 54 Potential H-bonds were assigned if the distance between two electronegative atoms was less than 3.3 Å, whereas any separation greater than 3.3 Å, but less than 4.0 Å, was considered a vdW interaction.
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Results and discussion
Validation of docking method
The ligands; diazepam, ibuprofen (at two binding sites referred to ibuprofen 1 and ibuprofen 2) and warfarin were first extracted from the corresponding coordinate files; 2BXF, 2BXG and 2BXD, then ligands was found to exactly dock into its corresponding ligand binding site in the protein structure.
This provides a positive validation of the docking method used in the study.
Docking studies
Two different types of docking runs were performed whereby; i) the ligand is centered and docked at a 5 specified binding site and ii) the ligand is docked automatically in a binding site defined by the program.
Using the docking based approach on a pre-aligned ligand binding site, each of the modelled and minimized titanocene derivatives were docked sequentially into all four different ligand binding sites; 10 warfarin, diazepam and the two ibuprofen sites used in the study. This is in addition to an automated docking process into the prepared HSA of (1E7E) which was not based on any ligand binding site, and a further docking process based on the fatty acid (capric acid) binding sites FA1, 2 and 5 of 1E7E (as defined by Curry et al.). Bis-amino-functionalized titanocenes, compounds 3a, 3b and 3c docked into the warfarin binding site of 2BXD showed that titanocene 3a formed only one H-bond, between its chlorine center Cl(1) and the nitrogen atom NE2 of His242. In comparison titanocene 3b formed three H-bonds, one between Cl (1) and His242 and the other two between N(4), S (2) Ser489. Compound 2b was also found to form a single H-bond between Cl(1) and OH group of Tyr411, whereas compound 2c showed four H-bond interactions, two formed through Cl(2) with both OG atom of Ser489 and OH group of Tyr411, and two formed between its N(1) with side chain atoms NE and NH2 of Arg410. 
Docking at the ibuprofen binding site of (2BXG)
No polar contacts were found with any of the amino acid residues upon docking of titancenes 1a and 1d into the ibuprofen binding site of 2BXG, whereas docking of 1b and 1c showed H-bonds between their chlorines with both Arg410 and Asn391. of six H-bonds, two between its chlorines to Ser489 and Asn391, two between the oxygen center O (4) to Asn391, and two through O(1), N(5) atoms to Arg410 and Ser489, respectively. Compound 3b was found to form five H-bonds, three by its chlorines to Lys414 and Ser489 and two by S(4) with Asn391.
And compound 3c exhibited a network of five potential H-bonds through its chlorines with Arg410 and Asn391. Automated docking revealed that these titanocenes can bind at a different site than previously identified for HSA. In fact, instead of binding to either known drug binding sites I and II, these compounds appear to span a large region making several potential H-bonds and vdW interactions with amino acid residues from both known drug binding sites, drug site I and II on HSA. This is not surprising when the actual size of these compounds is taken into account. HSA on the cytotoxic activity of these compounds.
Comparison of mono-and di-heteroaryl substituted titanocenes with the N-methyl pyrrol substitution, 2c and 4c showed that compound 4c exhibited higher number of vdW interactions at drug sites I and II 30 than did compound 2c which could explain the differences in their cytotoxic activity.
Furthermore, although compound 4c makes fewer H-bonds compared to 4a or 4b, it has higher cytotoxic activity than either 4a or 4b. This may suggest that vdW interactions play an important role in its binding mode to HSA, hence the outcome on cytotoxic activity (since 4c makes a larger number of vdW interactions with residues in the warfarin binding site).
On the other hand, diaryl-substituted titanocene 5b have higher cytotoxic activity when compared to 5 the monoaryl-substituted titanocene 1a. This is probably because of large number of H-bonds that titanocene 5b formed with the amino acid residues of both drug site I and drug site II of HSA.
These differences highlighted the importance of molecular descriptors, such as H-bonding potential, lipophilicity and shape complemantarity in determining the binding mode to HSA. 10 The docking results to date indicate that these titanocenes can make several interactions through H- 1a-d, 2a-c, 3a-c, 4a-c, 5a-c 
Text
A molecular docking study of novel titanocene derivatives to human serum album reveals 10 potential modes of binding to the known drug binding sites and highlights a potential new binding site for these derivatives.
